Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

About Can-Fite BioPharma

About Us

Overview
Company Leadership 
 

 

Overview

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.

 

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects.

 
An advanced clinical stage
drug devlopment company
 

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. CF101, Can-Fite`s lead drug candidate, is in advanced clinical development for the treatment of autoimmune-inflammatory diseases, including Rheumatoid Arthritis (RA) and Psoriasis. Can-Fite holds 82% in OphthaliX Inc. (OTCBB: OPLI) which develops CF101 for ophthalmic indications, including Dry Eye Syndrome, Glaucoma and Uveitis. CF102, Can-Fite`s second drug candidate, is being developed for the treatment of Hepatocellular Carcinoma (Primary Liver Cancer), under an Orphan Drug Status designated by the FDA. CF602 is Can-Fite’s second generation allosteric drug candidate for the treatment of inflammatory diseases, which has shown proof of concept in in vitro and in vivo studies. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

 

Can-Fite has licensed CF101 for the treatment of autoimmune diseases to Seikagaku Corporation (SKK) in Japan and for RA to Kwang Dong in Korea. Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.